VIDEO: ‘The future is bright’ for patients treated with RBX2660 for C. difficile

ByPaul Feuerstadt, MD, FACG, AGAF

ByKate Burba

SAN DIEGO — In a Healio video exclusive from Digestive Disease Week 2022, Paul Feuerstadt, MD, FACG, AGAF, discussed studies assessing the investigational biotherapeutic, RBX2660, for the treatment of Clostridioides difficile.

“RBX2660 has consistent safety and efficacy regardless of the patient's medical history as well as their demographics; this again applies to the notion that patients can broadly be treated with this and have a very effective symptomatic relief of their recurrent C. difficile in a sustained fashion,” Feuerstadt, assistant clinical professor of medicine at Yale University School of Medicine, said. “The future is truly bright for patients with recurrent C. difficile infection as we gain more and more data showing a broad applicability of products like RBX2660.”

References:

Feuerstadt P, et al. Abstract Su1600. Presented at: Digestive Disease Week; May 21-24, 2022; San Diego (hybrid meeting).
Feuerstadt P, et al. Abstract Su1608. Presented at: Digestive Disease Week; May 21-24, 2022; San Diego (hybrid meeting).

Published by:

Sources/Disclosures

Collapse

Source:

Feuerstadt P, at al. Abstract 892. Presented at: Digestive Disease Week; May 21-24, 2022; San Diego (hybrid meeting).

Disclosures: Feuerstadt reports personal fees from Ferring/Rebiotix, Merck and Co., Seres Therapeutics and Takeda Pharmaceuticals.

Digestive Disease Week

Read more

VIDEO: ‘The future is bright’ for patients treated with RBX2660 for C. difficile

References:

Related Content